{"id":"praga-formulation","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Pneumonitis"},{"rate":"1-5%","effect":"Hypothyroidism"},{"rate":"1-5%","effect":"Hyperthyroidism"},{"rate":"1-5%","effect":"Diarrhea"},{"rate":"1-5%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL3301675","moleculeType":"Protein","molecularWeight":"1526.77"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Praga formulation is designed to inhibit the interaction between PD-1 and PD-L1, which can help to restore the body's immune response against cancer cells. This can lead to the reduction of tumor growth and the slowing of disease progression.","oneSentence":"Praga formulation is a drug that works by targeting the PD-1/PD-L1 pathway to modulate the immune system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:46.634Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT04666714","phase":"PHASE3","title":"Efficacy and Safety of Praga Formulation in the Treatment of Neuropathic Pain","status":"RECRUITING","sponsor":"EMS","startDate":"2023-05-15","conditions":"Neuropathic Pain","enrollment":136}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Praga formulation","genericName":"Praga formulation","companyName":"EMS","companyId":"ems","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Praga formulation is a drug that works by targeting the PD-1/PD-L1 pathway to modulate the immune system. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}